By Billy Candra 
Deciding whether to start hormone therapy (HT) during the menopause transition, the life phase that marks the cessation of a woman’s menstrual cycle and serves as the bookend to puberty, has long been a subject of intense debate within the medical community and among patients. While hormone therapy, which involves replacing hormones previously produced by the body with synthetic medication, is widely recommended for managing bothersome symptoms such as hot flashes and night sweats, a pervasive confusion has existed regarding its long-term effects, particularly concerning cardiovascular health. This uncertainty stems from a complex history of research and evolving medical understanding.
The Evolving Landscape of Menopause Hormone Therapy
For decades, hormone therapy was a cornerstone of menopausal care, prescribed liberally to alleviate symptoms and even for perceived anti-aging benefits. Millions of women globally utilized estrogen-based therapies, driven by the belief in their comprehensive health advantages. However, this widespread acceptance was dramatically challenged in the early 2000s by the initial findings of the Women’s Health Initiative (WHI), a landmark national study. The WHI’s initial reports indicated potential risks, including an increased risk of breast cancer, heart attack, stroke, and blood clots in certain groups of women receiving combined estrogen and progestin therapy. These findings led to a precipitous decline in HT prescriptions, widespread alarm, and a significant shift in medical guidelines, urging caution and limiting HT use to the lowest effective dose for the shortest possible duration.
The ensuing years saw extensive re-analysis of the WHI data and the emergence of new research, gradually refining the understanding of HT. Experts began to emphasize the importance of the "timing hypothesis" or "window of opportunity," suggesting that the benefits and risks of HT might vary significantly depending on a woman’s age and how soon after menopause onset she begins therapy. It became increasingly recognized that for younger menopausal women (typically within 10 years of menopause onset) who are generally healthy and have no known cardiovascular disease, the benefits of HT for symptom management often outweigh the risks. Despite this evolving consensus, the specter of cardiovascular risk, particularly regarding long-term use, has continued to fuel apprehension among both patients and healthcare providers.
A Fresh Look at Long-Term Cardiovascular Effects
Against this backdrop of ongoing discussion and clinical uncertainty, a new study led by Matthew Nudy, an assistant professor of medicine at the Penn State College of Medicine, has offered compelling insights into the long-term effects of estrogen-based hormone therapies on heart health. The multi-institutional research team meticulously analyzed data from hormone therapy clinical trials that were integral components of the Women’s Health Initiative. Their findings suggest that estrogen-based hormone therapy may have beneficial effects on a range of biomarkers associated with cardiovascular health over an extended period. Crucially, the study points to a potential role for hormone therapy in lowering levels of lipoprotein(a), a largely genetic risk factor strongly linked to a heightened risk of heart attack and stroke.
The findings, published in the prestigious journal Obstetrics & Gynecology, contribute significantly to the understanding of the intricate interplay between hormone therapy and cardiovascular well-being. This research provides additional, much-needed guidance for both patients navigating their menopause journey and the clinicians advising them. "The pendulum has been swinging back and forth as to whether hormone therapy is safe for menopausal women, especially from a cardiovascular disease perspective," Nudy stated, underscoring the historical volatility of the debate. "More recently, we’re recognizing that hormone therapy is safe in younger menopausal women within 10 years of menopause onset, who are generally healthy and who have no known cardiovascular disease." This statement reflects the current nuanced understanding that has emerged post-WHI.
The Menopause-Cardiovascular Disease Connection
Menopause is not merely characterized by disruptive symptoms like hot flashes, night sweats, and mood swings. The profound hormonal changes that accompany this phase of life usher in another significant physiological shift: an increased risk of cardiovascular disease (CVD). The decline in estrogen, a hormone known for its cardioprotective effects, can trigger adverse changes in cholesterol profiles, blood pressure regulation, and contribute to the accelerated buildup of plaque in blood vessels (atherosclerosis). These changes collectively elevate a woman’s susceptibility to heart attack and stroke, making cardiovascular health a critical concern during and after menopause. Indeed, heart disease remains the leading cause of death for women globally, with risk escalating significantly post-menopause.
Prior research in this field predominantly focused on the short-term effects of hormone therapy on cardiovascular markers. The research team, however, sought to address a critical gap by investigating the long-term impact of hormone therapy on cardiovascular biomarkers, an area that had not been comprehensively evaluated over an extended period. This long-term perspective is vital for understanding the true clinical implications of a therapy often considered for sustained use.
Methodology: Revisiting WHI Data with a Long-Term Lens
To achieve their objective, the research team undertook an in-depth analysis of cardiovascular biomarkers over a six-year period. Their dataset was derived from a carefully selected subset of women who had participated in an oral hormone therapy clinical trial, a cornerstone of the broader Women’s Health Initiative. Participants in the original trial were randomly assigned to one of two distinct groups: an estrogen-only group, typically for women who had undergone a hysterectomy and thus did not require progesterone to protect the uterine lining, and an estrogen-plus-progesterone group, for women with an intact uterus. All participants were post-menopausal and ranged in age from 50 to 79 years at the time of group assignment.
Blood samples were systematically collected at baseline, and then at follow-up intervals of one, three, and six years, providing a robust longitudinal view of biomarker changes. In total, the researchers analyzed samples from 2,696 women, representing approximately 10% of the total participants in the original clinical trial. This substantial sample size and the rigorous methodology of the original WHI trials lent significant statistical power and validity to the current study’s findings. The WHI, launched in 1991, was a massive undertaking, enrolling over 161,000 postmenopausal women aged 50–79 years, and its vast repository of data continues to be an invaluable resource for understanding women’s health.
Key Findings: Beyond Traditional Cholesterol Markers
The comprehensive analysis revealed that hormone therapy exerted a beneficial effect on the majority of cardiovascular biomarkers across both the estrogen-only and the estrogen-plus-progesterone groups over the six-year observation period. Specifically, levels of low-density lipoprotein (LDL) cholesterol, often termed the "bad" cholesterol due to its role in arterial plaque formation, were notably reduced by approximately 11%. Concurrently, total cholesterol levels and measures of insulin resistance—a precursor to type 2 diabetes and a significant cardiovascular risk factor—also demonstrated decreases in both treatment arms. Conversely, high-density lipoprotein (HDL) cholesterol, widely recognized as the "good" cholesterol for its role in transporting cholesterol away from arteries, saw increases of 13% in the estrogen-only group and 7% in the estrogen-and-progesterone groups, respectively. These improvements in lipid profiles and insulin sensitivity align with expected cardioprotective effects of estrogen.
However, the study also observed increases in triglycerides, another type of fat in the blood, and in coagulation factors, which are proteins in the blood essential for forming blood clots. While these increases could potentially be concerning, their clinical significance must be weighed against the overall beneficial shifts in other markers and the specific type of oral estrogen used in the trial, as discussed further below.
Lipoprotein(a): A Breakthrough Discovery
Perhaps the most surprising and clinically impactful finding from the research team was the significant reduction in levels of lipoprotein(a) (Lp(a)), a unique and often overlooked type of cholesterol molecule. Lp(a) levels decreased by an impressive 15% in the estrogen-only group and 20% in the estrogen-plus-progesterone groups. Unlike other forms of cholesterol, which can be profoundly influenced by lifestyle factors such as diet, exercise, and smoking, concentrations of lipoprotein(a) are predominantly determined by an individual’s genetics. High concentrations of Lp(a) are a potent and independent genetic risk factor for an increased risk of heart attack and stroke, often at a younger age than typically observed. Furthermore, elevated Lp(a) is associated with an increased risk of aortic stenosis, a condition where calcium builds up on the heart valve, restricting blood flow.
"As a cardiologist, this finding is the most interesting aspect of this research," Dr. Nudy emphasized. "Currently, there are no medications approved by the Food and Drug Administration (FDA) specifically designed to lower lipoprotein(a). Here, we essentially found that oral hormone therapy significantly reduced lipoprotein(a) concentrations over the long-term." This discovery is monumental because it identifies a readily available therapeutic option that could potentially mitigate a significant, genetically determined cardiovascular risk factor for which no targeted treatments currently exist. This could open new avenues for risk management in individuals with high Lp(a) levels. It is estimated that approximately 1 in 5 people worldwide have elevated Lp(a), making this a widespread concern.
Unraveling Racial and Ethnic Disparities
The research team further investigated their findings by examining them across self-reported racial and ethnic groups. They uncovered an intriguing and potentially vital disparity: the decrease in lipoprotein(a) concentration was significantly more pronounced among participants with American Indian or Alaska Native ancestry, showing a remarkable 41% reduction, and among those with Asian or Pacific Islander ancestry, where a 38% decrease was observed. Dr. Nudy acknowledged that the precise reasons behind these steeper reductions in specific ancestral groups are not yet clear. However, he expressed the team’s intention to thoroughly investigate this phenomenon in future research studies. Understanding these differences could lead to more personalized and effective treatment strategies tailored to specific populations.
Oral vs. Transdermal: Nuances in Delivery and Metabolism
Dr. Nudy also provided crucial context regarding the type of estrogen therapy administered in the clinical trial: conjugated equine estrogens, a commonly prescribed form of oral estrogen therapy. He highlighted an important pharmacological distinction: oral hormone therapy undergoes a process called "first-pass metabolism" in the liver before it is absorbed into the general circulation. This hepatic processing can potentially increase inflammatory markers, which might explain the observed rise in triglycerides and coagulation factors in the study.
This insight leads to a critical discussion about different formulations of estrogen therapy. "There are now other common formulations of estrogen hormone therapy like transdermal estrogen, which is administered through the skin," Nudy explained. "Newer studies have found that transdermal estrogen doesn’t increase triglycerides, coagulation factors or inflammatory markers." This distinction is significant because transdermal formulations bypass the liver’s first-pass metabolism, potentially offering a more favorable safety profile regarding these specific markers. This underscores the importance of personalized medicine, where the choice of hormone therapy formulation can be tailored to an individual’s risk profile and specific health needs.
Clinical Implications and Expert Recommendations
The findings from this study carry substantial clinical implications. While the current research does not alter the FDA’s stance—that hormone therapy is not approved to reduce the risk of coronary artery disease or stroke—it certainly strengthens the argument for a more nuanced and individualized approach to menopausal hormone therapy. For individuals contemplating menopause hormone therapy, Dr. Nudy strongly recommended undergoing a comprehensive cardiovascular disease risk assessment. This assessment is crucial even if the person has no prior history of heart attack or stroke, or has not been previously diagnosed with cardiovascular disease. Such an evaluation provides healthcare providers with more detailed information, enabling them to make the most informed decision about the optimal treatment option for managing menopause symptoms while simultaneously considering long-term cardiovascular health.
Leading medical organizations, such as the North American Menopause Society (NAMS) and the American College of Obstetricians and Gynecologists (ACOG), already advocate for individualized decision-making regarding HT, emphasizing a thorough discussion of benefits and risks with a healthcare provider. This new research, particularly concerning lipoprotein(a), adds another layer of complexity and potential benefit to this discussion, potentially shifting the risk-benefit analysis for certain women.
Future Directions in Menopause Research
This study is not merely an endpoint but a catalyst for further research. The discovery of HT’s impact on lipoprotein(a) warrants dedicated studies to explore this mechanism further and to investigate whether other forms of estrogen therapy, particularly transdermal, yield similar reductions without the increase in triglycerides and coagulation factors seen with oral formulations. The observed racial and ethnic disparities in Lp(a) reduction also necessitate focused investigation to understand the underlying biological or genetic factors. Such research could lead to the development of more equitable and effective menopause management strategies across diverse populations.
Furthermore, continued long-term follow-up of WHI participants and other cohorts will be essential to confirm these findings and to explore other potential long-term effects of hormone therapy on cardiovascular health and overall well-being. The collaborative nature of this research, involving multiple institutions and experts, highlights the importance of interdisciplinary approaches to tackling complex health questions. The study’s authors include Aaron Aragaki from Fred Hutchinson Cancer Center; Peter Schnatz and Xuezhi Jiang from Drexel University College of Medicine; JoAnn Manson from Brigham and Women’s Hospital, Harvard Medical School, and Harvard T.H. Chan School of Public Health; Aladdin Shadyab from the University of California San Diego; Su Yong Jung from the University of California Los Angeles; Lisa Martin from The George Washington University; Robert Wild from the University of Oklahoma Health Sciences Center; Catherine Womack from the University of Tennessee Health Science Center; Charles Mouton from the University of Texas Medical Branch; and Jacques Rossouw, formerly of the National Heart, Lung, and Blood Institute at the National Institutes of Health. Funding from the National Center for Advancing Translational Sciences supported this vital work, underscoring its significance for public health.
In conclusion, this new research offers a significant contribution to the evolving understanding of menopause hormone therapy. By demonstrating long-term beneficial effects on key cardiovascular biomarkers, particularly the reduction of genetically determined lipoprotein(a), it provides compelling evidence that, for appropriately selected women, hormone therapy may offer more than just symptom relief, potentially playing a role in mitigating cardiovascular risk. This study reinforces the current medical consensus that personalized risk assessment and informed patient-provider dialogue are paramount in navigating the complexities of menopause management.
